Request Demo
Last update 18 Aug 2026
SYS-6090
Last update 18 Aug 2026
Overview
Basic Info
Drug Type Fc fusion protein |
Synonyms JMT-108, JMT108, SYS6090 |
Target |
Action modulators, inhibitors |
Mechanism IL-15 modulators(Interleukin-15 modulators), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with SYS-6090NCT07761286
Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of Combination Therapy With SYS6090 Injection in Participants With Hepatocellular Carcinoma
NCT07750041
A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Coloretal Cancer
NCT07472647
A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer
100 Clinical Results associated with SYS-6090
Login to view more data
100 Translational Medicine associated with SYS-6090
Login to view more data
100 Patents (Medical) associated with SYS-6090
Login to view more data
100 Deals associated with SYS-6090
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Colorectal Adenocarcinoma | Phase 2 | China | 30 Aug 2026 | |
| Metastatic Colorectal Carcinoma | Phase 2 | China | 30 Aug 2026 | |
| Hepatocellular Carcinoma | Phase 2 | China | 31 Jul 2026 | |
| Extensive stage Small Cell Lung Cancer | Phase 2 | - | 28 Feb 2026 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | - | 28 Feb 2026 | |
| Locally Advanced Lung Carcinoma | Phase 2 | China | 13 Feb 2026 | |
| Metastatic melanoma | Phase 2 | China | 17 Dec 2025 | |
| Unresectable Melanoma | Phase 2 | China | 17 Dec 2025 | |
| Urologic Neoplasms | Phase 2 | China | 17 Dec 2025 | |
| Advanced cancer | Phase 2 | China | 11 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free